Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus von Chung, Raymond T., Davis, Gary L., Jensen, Donald M., Masur, Henry, Saag, Michael S., Thomas, David L., Aronsohn, Andrew I., Charlton, Michael R., Feld, Jordan J., Fontana, Robert J., Ghany, Marc G., Godofsky, Eliot W., Graham, Camilla S., Kim, Arthur Y., Kiser, Jennifer J., Kottilil, Shyam, Marks, Kristen M., Martin, Paul, Mitruka, Kiren, Morgan, Timothy R., Naggie, Susanna, Raymond, Daniel, Reau, Nancy S., Schooley, Robert T., Sherman, Kenneth E., Sulkowski, Mark S., Vargas, Hugo E., Ward, John W., Wyles, David L.

Volltext

Sinusitis in HIV-infected patients: A clinical and radiographic review von Godofsky, Eliot W., Zinreich, James, Armstrong, Michael, Leslie, Jo M., Weikel, Cynthia S.

Volltext

Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension von Bach, M C, Tally, P W, Godofsky, E W

Volltext

Treatment of Presumed Cerebral Toxoplasmosis with Azithromycin: Letter von Godofsky, Eliot W

Volltext

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 von Naggie, Susanna, Cooper, Curtis, Saag, Michael, Workowski, Kimberly, Ruane, Peter, Towner, William J, Marks, Kristen, Luetkemeyer, Anne, Baden, Rachel P, Sax, Paul E, Gane, Edward, Santana-Bagur, Jorge, Stamm, Luisa M, Yang, Jenny C, German, Polina, Dvory-Sobol, Hadas, Ni, Liyun, Pang, Phillip S, McHutchison, John G, Stedman, Catherine A.M, Morales-Ramirez, Javier O, Bräu, Norbert, Jayaweera, Dushyantha, Colson, Amy E, Tebas, Pablo, Wong, David K, Dieterich, Douglas, Sulkowski, Mark

Volltext

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection von Gulick, Roy M, Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B, McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W, van der Ryst, Elna, Mayer, Howard

Volltext

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection von Fätkenheuer, Gerd, Nelson, Mark, Lazzarin, Adriano, Konourina, Irina, Hoepelman, Andy I.M, Lampiris, Harry, Hirschel, Bernard, Tebas, Pablo, Raffi, François, Trottier, Benoit, Bellos, Nicholaos, Saag, Michael, Cooper, David A, Westby, Mike, Tawadrous, Margaret, Sullivan, John F, Ridgway, Caroline, Dunne, Michael W, Felstead, Steve, Mayer, Howard, van der Ryst, Elna

Volltext

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study von Manns, Michael P., Gane, Edward, Rodriguez-Torres, Maribel, Stoehr, Albrecht, Yeh, Chau-Ting, Marcellin, Patrick, Wiedmann, Richard T., Hwang, Peggy M., Caro, Luzelena, Barnard, Richard J.O., Lee, Andrew W.

Volltext

Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1 von Kuritzkes, Daniel R., Jacobson, Jeffrey, Powderly, William G., Godofsky, Eliot, DeJesus, Edwin, Haas, Frances, Reimann, Keith A., Larson, Jeffrey L., Yarbough, Patrice O., Curt, Valentin, Shanahan, William R.

Volltext

R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin von Pockros, Paul J., Nelson, David, Godofsky, Eliot, Rodriguez‐Torres, Maribel, Everson, Gregory T., Fried, Michael W., Ghalib, Reem, Harrison, Stephen, Nyberg, Lisa, Shiffman, Mitchell L., Najera, Isabel, Chan, Anna, Hill, George

Volltext

Racial differences in hepatitis C treatment eligibility von Melia, Michael T., Muir, Andrew J., McCone, Jonathan, Shiffman, Mitchell L., King, John W., Herrine, Steven K., Galler, Greg W., Bloomer, Joseph R., Nunes, Frederick A., Brown, Kimberly A., Mullen, Kevin D., Ravendhran, Natarajan, Ghalib, Reem H., Boparai, Navdeep, Jiang, Ruiyun, Noviello, Stephanie, Brass, Clifford A., Albrecht, Janice K., McHutchison, John G., Sulkowski, Mark S.

Volltext

High relapse rate seen at week 72 for patients treated with R1626 combination therapy von Pockros, Paul, Nelson, David, Godofsky, Eliot, Rodriguez‐Torres, Maribel, Everson, Gregory T., Fried, Michael W., Ghalib, Reem, Harrison, Stephen, Nyberg, Lisa, Shiffman, Mitchell L., Chan, Anna, Hill, George

Volltext